Amgen's Imdelltra used in combination with AstraZeneca's immunotherapy Imfinzi reduced the risk of ‌death by 58% compared to the Astra drug alone in patients with extensive-stage small cell lung cancer, according to data from a study presented at a major medical meeting on Saturday.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in